Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(409)
•••
Comment by bringon10baggeron Apr 08, 2020 11:22am
235 Views
Post# 30890360

RE:RE:RE:RE:RE:Re: End of April

RE:RE:RE:RE:RE:Re: End of AprilAgree unfair criticism, Cyrol has a pattern of being a basher of Dan, a long history here??? Unfortunately physical distancing is probably slowing analysis of data, and realistically Dan is not going to disclose the day of results but just generalize. Mgmt has never sacrificed their integrity. IMO by EOW Apr 20 results will be out, I'm sticking to APRIL 21st..........listen for the pop, pop, pop of the champagne bottles........
Marky1 wrote: I'm coming out from under my bed...Dan Legault is, I feel, doing a great job with ATE IMHO...I don't agree with this bashing...The IR has told me, personally, that the results will be out after Easter and Passover....Plus they'd rather give it out on a Monday rather than a Friday

April 20 th.  Is the day that we are all going to see the results
GLTA



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities